PainReform Ltd. (NASDAQ:PRFX) Short Interest Down 54.2% in January

PainReform Ltd. (NASDAQ:PRFX) saw a large decrease in short interest in January. As of January 15th, there was short interest totalling 25,600 shares, a decrease of 54.2% from the December 31st total of 55,900 shares. Based on an average daily volume of 3,390,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 3.0% of the company’s stock are short sold.

PainReform Trading Down 2.2 %

Shares of PRFX traded down $0.08 on Thursday, reaching $3.27. The company’s stock had a trading volume of 71,809 shares, compared to its average volume of 1,127,865. PainReform has a twelve month low of $1.73 and a twelve month high of $61.20. The stock has a market capitalization of $473,425.00, a PE ratio of -0.02 and a beta of 0.64. The firm has a fifty day moving average of $3.42 and a 200-day moving average of $2.61.

Institutional Investors Weigh In On PainReform

A hedge fund recently bought a new stake in PainReform stock. Apollon Wealth Management LLC acquired a new stake in PainReform Ltd. (NASDAQ:PRFX) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 12,917 shares of the company’s stock, valued at approximately $43,000. Apollon Wealth Management LLC owned about 9.23% of PainReform as of its most recent filing with the SEC. 37.28% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Maxim Group reissued a “hold” rating on shares of PainReform in a research report on Thursday, October 24th.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.